Supplement evidence
Omega-3
The depression meta-analyses, the EPA/DHA split, and the heterogeneity problem.
What Its Legal Status Actually Means
Read this before anything below it. Legal to sell is not the same fact as reviewed, verified, or approved.
Fish-oil, EPA and DHA products sold for mood are dietary supplements under DSHEA: no FDA review of safety or effectiveness happens before they go on sale, and none is approved to treat depression or any other psychiatric condition. Prescription omega-3 drugs do exist, but for lipids, not mood. Icosapent ethyl (Vascepa) is FDA-approved as an adjunct to maximally tolerated statin therapy to reduce cardiovascular events in adults with triglycerides at or above 150 mg/dL plus established cardiovascular disease or diabetes, and as an adjunct to diet for severe (at or above 500 mg/dL) hypertriglyceridemia; omega-3-acid ethyl esters (Lovaza and generics) are approved only as an adjunct to diet for severe hypertriglyceridemia. Neither label carries a psychiatric indication. Dose matters and labels obscure it: the depression literature is dosed in grams of EPA, while a capsule marked "fish oil 1000 mg" typically contains only a few hundred milligrams of EPA, so the number on the front of the bottle is usually not the number the trials used.
Quoted whole from the 2026-08-18 study harvest. Not summarized, not shortened.
What the Research Shows
4 records from the 2026-08-18 harvest, each checked against PubMed and Europe PMC on that date. How a study was designed, how many people were in it, and who paid for it are printed above what it found, because those three facts decide how much the finding is worth.
Study 1 · 2021
- Systematic review of randomized trials
- 1,924 participants
- Top-tier journal
- Independently funded
- Preregistered
- Declared conflicts of interest
gold standard97/100Top of the evidence hierarchy, independently funded.
Across 35 randomised trials (34 versus placebo, 1,924 adults with major depressive disorder), omega-3 supplementation produced a small-to-modest reduction in depressive symptoms — standardised mean difference -0.40 (95% CI -0.64 to -0.16), which the authors translate to roughly 2.5 points on the 17-item Hamilton scale, below the 3.0-point change usually considered clinically meaningful. There was no evidence of a difference in remission (OR 1.13, 95% CI 0.74 to 1.72) or response (OR 1.20, 95% CI 0.80 to 1.79). The reviewers graded the evidence very low certainty and reported that funnel-plot inspection, sensitivity analyses, and comparison with large well-conducted trials all suggest the estimate is biased in omega-3's favour.
How this record was checked
PubMed record 34817851 fetched via NCBI efetch 2026-08-18; title, all seven authors, journal, year, DOI, N=1924 participants across 35 studies, and the SMD -0.40 (95% CI -0.64 to -0.16) confirmed from the abstract. PMC full text PMC8612309 read 2026-08-18: "Sources of support" lists Bournemouth University and University of Bristol (internal) and the National Institute for Health Research (external), hence funding INDEPENDENT; the same page records "Protocol first published: Issue 1, 2004", hence preregistered true, and a per-author declarations-of-interest section, hence conflicts true.
Study 2 · 2021
- Randomized trial
- 18,353 participants
- Top-tier journal
- Mixed funding
- Preregistered
- Declared conflicts of interest
gold standard85/100Top of the evidence hierarchy, independently funded.
Read this first: The higher depression rate was a borderline result on one of two coprimary outcomes while the other (mood scores) showed nothing at all; the authors did not claim omega-3 causes depression, and this was a prevention trial in people without clinically relevant depressive symptoms at baseline, so it does not test omega-3 as a treatment for existing depression. Study capsules and matching placebo were donated by Pronova BioPharma, an industry in-kind contribution, though the trial itself was NIH-funded, the funders had no role, and the result was unfavourable to the product.
In 18,353 US adults aged 50 and older randomised to 1 g/day of marine omega-3 (465 mg EPA plus 375 mg DHA) or matching placebo for a median 5.3 years, omega-3 did not prevent depression: depression or clinically relevant depressive symptoms occurred at 13.9 per 1,000 person-years on omega-3 versus 12.3 on placebo (HR 1.13, 95% CI 1.01 to 1.26, P=.03) — a small but statistically significant increase in risk. Mood scores did not differ (mean PHQ-8 change difference 0.03 points, 95% CI -0.01 to 0.07). The authors concluded the findings do not support using omega-3 supplements to prevent depression in adults.
How this record was checked
PubMed record 34932079 fetched via NCBI efetch 2026-08-18; title, authors, journal (JAMA 2021;326(23):2385-2394), DOI, N=18,353 randomised, the hazard ratio, and the PHQ-8 difference confirmed from the abstract, along with trial registrations NCT01696435 and NCT01169259 (hence preregistered true) and a conflict-of-interest disclosure statement (hence conflicts true). Europe PMC core record fetched 2026-08-18 lists NIH grants including R01 MH091448 (NIMH). PMC full text PMC8693224 read 2026-08-18: "Funding/Support" confirms NIH grant support and states "The study agents, matching placebo, and packaging were donated by Pharmavite LLC (vitamin D) and Pronova BioPharma (fish oil)" — public funding with industry in-kind product, hence MIXED.
Study 3 · 2019
- Meta-analysis of randomized trials
- 2,160 participants
- Reputable journal
- Independently funded
- Declared conflicts of interest
gold standard89/100Top of the evidence hierarchy, independently funded.
Read this first: The paper carries a published erratum (Transl Psychiatry 2021;11(1):465) and a published critique (Transl Psychiatry 2022;12(1):298); neither is a retraction, but both belong alongside it. Dose and formulation subgroups drawn out of a meta-analysis of heterogeneous small trials are exploratory — the Cochrane review reached a similar overall effect size and judged it very low certainty and likely biased upward.
Pooling 26 double-blind placebo-controlled trials (2,160 participants), omega-3 had an overall effect on depressive symptoms of SMD -0.28 (P=0.004) — small. The benefit was concentrated in formulations that were pure EPA or at least 60% EPA at doses of 1 g/day or less of EPA (SMD -0.50 and -1.03 respectively), while DHA-pure and DHA-predominant formulations showed no benefit. The pooled effect is smaller than the change most clinicians would notice, and the subgroup pattern is a hypothesis about dosing, not a tested rule.
How this record was checked
PubMed record 31383846 fetched via NCBI efetch 2026-08-18; title, all nine authors, journal, year, DOI, 26 studies, N=2,160 participants, and SMD -0.28 (P=0.004) confirmed from the abstract, which also carries the statement "The authors declare that they have no conflict of interest" (hence conflicts true) and the "Erratum in" and "Comment in" flags noted above. Europe PMC core record fetched 2026-08-18 lists a single funder, the National Natural Science Foundation of China, hence funding INDEPENDENT.
Study 4 · 2019
- Clinical guideline
- Reputable journal
- Funding not established
moderate60/100Reasonable evidence with real limitations.
Read this first: ISNPR is a society organised around nutritional psychiatry, so it is the proponent of the intervention it is writing guidelines for, and the panel includes investigators whose own omega-3 trials form part of the evidence base being summarised. Two letters challenging the guideline appeared in the same journal (Psychother Psychosom 2020;89(1):48, PMID 31655818, and the authors' reply at 89(1):49, PMID 31743919). No funding statement was located, so funding is recorded UNKNOWN.
An expert panel convened by the International Society for Nutritional Psychiatry Research used a literature review and Delphi consensus process to recommend, for major depressive disorder, either pure EPA or an EPA/DHA formula with a ratio above 2:1, at 1-2 g of net EPA daily, alongside proper diagnosis, measurement-based assessment, and monitoring for gastrointestinal and skin side effects. This is consensus expert opinion rather than new trial evidence, and it sits uneasily beside the Cochrane review's verdict that the certainty of the evidence is low to very low.
How this record was checked
PubMed record 31480057 fetched via NCBI efetch 2026-08-18; title, authors, journal (Psychother Psychosom 2019;88(5):263-273), year, and DOI confirmed against the record, along with the 1-2 g net EPA daily and EPA/DHA >2 recommendations quoted from the abstract. The two "Comment in" letters (PMIDs 31655818 and 31743919) were fetched in the same batch and their titles confirmed. Europe PMC core record checked 2026-08-18: no grant list and no funding statement available, so funding recorded UNKNOWN and conflicts false (no disclosure statement read).
The Risks
Nobody checks this purchase the way a prescription is checked. No prescriber reviews it against the rest of what you take, no pharmacist screens the interaction, and no regulator confirms the dose in the capsule before it is sold. That is why this section sits here at full length rather than as a footnote.
What the paragraph below covers:
- Heart and blood pressure
- Drug interactions
- Stomach and gut
Omega-3 supplements are generally well tolerated; the usual complaints are fishy aftertaste or burps, nausea, loose stools, and heartburn. Bleeding risk at ordinary supplement doses is largely theoretical — over a median 5.3 years at 1 g/day in 18,353 adults, gastrointestinal bleeding occurred in 2.6% on omega-3 versus 2.7% on placebo, and easy bruising in 24.8% versus 25.1%. The real signal appears at high prescription doses: the FDA label for icosapent ethyl (4 g/day EPA) carries warnings for atrial fibrillation or flutter requiring hospitalisation and for bleeding, with bleeding risk greater in people also taking aspirin, clopidogrel, or warfarin. People with fish or shellfish allergy can react to fish-derived products. The most important practical risk is not toxicity but substitution: the largest prevention trial found omega-3 did not prevent depression, and the Cochrane estimate of its treatment effect sits below the threshold for a clinically meaningful change, so relying on it instead of a treatment that works is the more likely harm.
What Is Not Known
The boundaries of the section above, in the harvest’s own words. What it excluded, why, and where it looked and found nothing. An absence of evidence is not evidence of absence, and it is not evidence of benefit either.
What Was Left Out, and Why
Quoted from the harvest, where these notes sat above the study list rather than after it. Where a note says “below” it means the studies in the section above.
- Individual small positive EPA trials (Peet 2002, Nemets 2002, Su 2003, etc.) excluded in favour of the Cochrane review and the dose meta-analysis below, which subsume them.
- The two published letters criticising the ISNPR guideline (PMIDs 31655818 and 31743919, both Psychother Psychosom 2020;89(1)) were fetched and are cited inside that study's contestedNote rather than listed as separate records.
- VITAL-DEP's vitamin-D arm and the omega-3 cardiovascular literature are out of scope; only the depression endpoint paper is included.
The Retraction Check
PubMed efetch records for all four PMIDs inspected 2026-08-18 for "Retraction in" flags; none present. Liao 2019 (31383846) carries an "Erratum in" (Transl Psychiatry 2021;11(1):465) and a published "Comment in" critique (Transl Psychiatry 2022;12(1):298) — neither is a retraction; both noted in contestedNote.
Questions for a Prescriber or Pharmacist
This page does not tell anyone to take Omega-3 or to avoid it. It is not able to: it does not know what else you take, what you have tried, or what you are treating. These are the questions each study above raises, written to be asked out loud.
- The best synthesis puts omega-3's effect on depression at about 2.5 points on a scale where 3 points is the smallest change that matters — is adding it worth it for me, or is that effort better spent on something with a bigger effect?
- The largest trial ever run found fish oil did not prevent depression and if anything nudged the risk slightly up — am I taking it for prevention, and if so is there any reason to keep going?
- If we're going to try omega-3 at all, does the product I'd be buying actually deliver about a gram of EPA a day, with EPA making up most of the total?
- One expert group recommends 1-2 grams of EPA a day for depression while the Cochrane review says the evidence is very low certainty — which of those should guide what I actually do?
And the one to ask at the counter, whatever the answers above turn out to be: given everything I am already taking, what would you want to know about Omega-3 before I put it in the same body?
Where This Page Comes From
Transcribed from the study-harvest-2026-08-18 record for omega-3, built into this page by scripts/supplement-ingest.mjs on 2026-09-07. Nothing here is fetched at page load, and nothing here was written by a model without a citation behind it.
| Source file | study-harvest/2026-08-18/omega-3.yaml |
|---|---|
| Source repo | REPTechnologies/avalo-backend |
| SHA-256 | c44385adfe003cb4e8a54afe446cd0925cb53893e0df90624d555bbc34217e53 |
| Also searched as | fish oil, EPA, DHA, n-3 PUFA, omega-3 fatty acids, krill oil, algal oil |
The Other Substances
- 5-HTP
- Ashwagandha
- Cannabidiol (CBD)
- Cannabis and THC
- Creatine
- Kratom
- L-Theanine
- Magnesium
- Melatonin
- Methylene Blue
- Microdosing
- N-Acetylcysteine (NAC)
- Phenibut
- SAMe
- St John’s Wort
- Valerian
Do any supplements actually work? asks the question across all of them. The full library has the medication records, the funding investigations, and the glossary.